Promising Biotech Stocks To Follow Today - May 7th

Key Points

• MarketBeat’s stock screener singled out argenx, Moderna, and Danaher as biotech names to watch today, noting they had the highest dollar trading volume among biotech stocks recently and that biotech shares are typically high‑risk, high‑reward due to clinical, patent, and regulatory drivers.
• argenx (ARGX) is advancing efgartigimod as its lead candidate for multiple autoimmune diseases and maintains a broad pipeline (ENHANZE SC, Empasiprubart, ARGX‑119) targeting neuromuscular and autoimmune indications.
• Moderna (MRNA) is focused on mRNA therapeutics and an extensive vaccine pipeline across infectious, rare, and immunological diseases, while Danaher (DHR) supplies bioprocess technologies, consumables, and manufacturing solutions that support biologics development and commercial production.

argenex, Moderna, and Danaher are the three Biotech stocks to watch today, according to MarketBeat's stock screener tool. Biotech stocks are shares of companies that use biological processes, genetic engineering, and molecular science to develop drugs, therapies, diagnostics, and related medical technologies. For investors, these stocks are often high-risk, high-reward because company valuations hinge on long development timelines, clinical trial results, patent and regulatory outcomes, and potential commercialization. These companies had the highest dollar trading volume of any Biotech stocks within the last several days.

argenex (ARGX)

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.

Read Our Latest Research Report on ARGX

Moderna (MRNA)

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.

Read Our Latest Research Report on MRNA

Danaher (DHR)

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.

Read Our Latest Research Report on DHR

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.